Induction chemotherapy in XXXX stage IIIa-b and IV and second-line treatment.

@entity1 @entity7324 @entity1149 @entity900 @entity1259 @entity420
This study investigates the treatment management and survival of inoperable advanced @entity1149 ( @entity1149 ) @entity1 . The objective was to treat all @entity1 with induction chemotherapy and then to stratify them for surgery, radiotherapy, second-line chemotherapy or supportive treatment. Of the 359 @entity1 enrolled in the study, 336 fulfilled the study criteria and were classified as follows: 90 stage IIIa, 135 stage IIIb and 111 stage IV. Histological types included 131 squamous cell, 123 @entity420 , 53 undifferentiated non-small, 15 large cell, 3 adenosquamous, 3 bronchoalveolar and 8 unclassified. For all @entity1 induction therapy involved @entity900 (CDDP) combined chemotherapy and 84% of the @entity1 were also treated with @entity7324 and @entity1259 . The mean number of courses was 4 (minimum 2, maximum 11). The result of induction therapy was 49% complete and partial for at least 8 weeks; with minor response included, the total response rate was 67.6%. Fourteen @entity1 (4.16%) achieved analytically complete response, 151 (45%) partial response and 62 (18.5%) minor response. The second-line treatment implemented was as follows: surgical excision, 22 @entity1 (Group A); radiotherapy, 106 @entity1 (Group B); chemotherapy, 91 @entity1 (Group C) and supportive treatment, 117 @entity1 (Group D). Median survival in months was 72 (range 5-120+), 12 (range 2-118), 15 (range 3-48) and 7 (range 3-120) for Groups A-D respectively. There was a statistically significant difference in survival in Group A @entity1 (p < 0.001) but no difference was observed between Groups B and C. Group D @entity1 had significantly lower survival than the other three groups. In conclusion, induction chemotherapy renders a reasonably high response rate in operable @entity1149 @entity1 and second-line radiotherapy treatment is not superior to second-line chemotherapy.
